Orphazyme provides regulatory update on arimoclomol, raises cash guidance

seekingalpha2021-10-05

Orphazyme A/S(NASDAQ:ORPH)announces regulatory updates for arimoclomol, for which it is seeking marketing authorization in both Europe and U.S. for the treatment of Niemann-Pick disease Type C. Shares...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

SHWong
2021-10-05
SHWong
Pls like
MuppyKoh
2021-10-05
MuppyKoh
Please like
- SHWong:
  Done
Nebhol
2021-10-05
Nebhol
Like comment
LEEPK
2021-10-05
LEEPK
like
- Nebhol:
  Like comment
Tck
2021-10-05
Tck
[开心]
- Tck:
  h
haiguan
2021-10-05
haiguan
Like pls
- ILFTS:
  Liked please

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1124184351?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-05 17:59","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1124184351","market":"us","top_or_hot":-1,"title":"Orphazyme provides regulatory update on arimoclomol, raises cash guidance","media":"seekingalpha","content":"<div>\n<p>Orphazyme A/S(NASDAQ:ORPH)announces regulatory updates for arimoclomol, for which it is seeking marketing authorization in both Europe and U.S. for the treatment of Niemann-Pick disease Type C.\nShares...</p>\n\n<a href=\"https://seekingalpha.com/news/3748882-orphazyme-provides-regulatory-update-on-arimoclomol-raises-cash-guidance\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme provides regulatory update on arimoclomol, raises cash guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme provides regulatory update on arimoclomol, raises cash guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 17:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748882-orphazyme-provides-regulatory-update-on-arimoclomol-raises-cash-guidance><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S(NASDAQ:ORPH)announces regulatory updates for arimoclomol, for which it is seeking marketing authorization in both Europe and U.S. for the treatment of Niemann-Pick disease Type C.\nShares...</p>\n\n<a href=\"https://seekingalpha.com/news/3748882-orphazyme-provides-regulatory-update-on-arimoclomol-raises-cash-guidance\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://seekingalpha.com/news/3748882-orphazyme-provides-regulatory-update-on-arimoclomol-raises-cash-guidance","article_id":"1124184351","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124184351","pubTimestamp":1633427971,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Orphazyme A/S(NASDAQ:ORPH)announces regulatory updates for arimoclomol, for which it is seeking mark","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Orphazyme提供阿里莫氯醇的监管更新，提高现金指导","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORPH":0.9},"content_text":"Orphazyme A/S(NASDAQ:ORPH)announces regulatory updates for arimoclomol, for which it is seeking marketing authorization in both Europe and U.S. for the treatment of Niemann-Pick disease Type C.\nShares up 1.5% premarket at $4.07.\nThe review process in Europe is underway. ORPH now anticipates a CHMP opinion in Q1 2022 compared to previous Q4 2021.\nIn U.S., the company requested and has been granted a Post-Action Type A meeting with the FDA, which has been scheduled for mid-October.\nAt this meeting, Orphazyme plans to engage in a dialogue with the FDA to better understand its decision in theComplete Response Letter issued in June 2021, as well as to discuss proposals to address key topics raised in the letter.\nAlso, the company has updated cash guidance and now expects to end 2021 with a cash position of DKK 80M compared to prior outlook of ~DKK 50M.\nThe improved guidance relates to the ongoing restructuring plan, which has enabled the company to deliver more than anticipated savings in terms of headcount and other costs.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":820780327,"gmtCreate":1633433008830,"gmtModify":1633433009381,"author":{"id":"4087529754286040","authorId":"4087529754286040","name":"SHWong","avatar":"https://static.tigerbbs.com/274f969ad8f1b9a4a87c520c04f905a0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820780327","repostId":1124184351,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820710612,"gmtCreate":1633431528969,"gmtModify":1633431529354,"author":{"id":"3585354270249282","authorId":"3585354270249282","name":"MuppyKoh","avatar":"https://static.tigerbbs.com/280b63f52e5976fb134c31bfb22ec07d","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820710612","repostId":1124184351,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6099586,"gmtCreate":1633432997768,"gmtModify":1634721379652,"authorId":4087529754286040,"author":{"id":4087529754286040,"authorId":4087529754286040,"name":"SHWong","avatar":"https://static.tigerbbs.com/274f969ad8f1b9a4a87c520c04f905a0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820710612,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":820735813,"gmtCreate":1633430869188,"gmtModify":1633430869834,"author":{"id":"3567411499210880","authorId":"3567411499210880","name":"Nebhol","avatar":"https://static.tigerbbs.com/b0bfc2a45b91e41a283614268857b3a5","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820735813","repostId":1124184351,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820735195,"gmtCreate":1633430835633,"gmtModify":1633430835875,"author":{"id":"3561626499477725","authorId":"3561626499477725","name":"LEEPK","avatar":"https://static.tigerbbs.com/797bbc4f6e8194fe6be369618bc544f5","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"like&nbsp;","listText":"like&nbsp;","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820735195","repostId":1124184351,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6099397,"gmtCreate":1633430875984,"gmtModify":1634721395517,"authorId":3567411499210880,"author":{"id":3567411499210880,"authorId":3567411499210880,"name":"Nebhol","avatar":"https://static.tigerbbs.com/b0bfc2a45b91e41a283614268857b3a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820735195,"type":1,"supId":0,"prevId":0,"content":"Like comment ","text":"Like comment ","html":"Like comment "}],"langContent":"CN"},{"id":820735041,"gmtCreate":1633430811391,"gmtModify":1633430811542,"author":{"id":"3583241719564784","authorId":"3583241719564784","name":"Tck","avatar":"https://static.tigerbbs.com/916da960b2815980b6534526bd75788b","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[开心]&nbsp;","listText":"[开心]&nbsp;","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820735041","repostId":1124184351,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6099391,"gmtCreate":1633430816058,"gmtModify":1634721395950,"authorId":3583241719564784,"author":{"id":3583241719564784,"authorId":3583241719564784,"name":"Tck","avatar":"https://static.tigerbbs.com/916da960b2815980b6534526bd75788b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820735041,"type":1,"supId":0,"prevId":0,"content":"<u>h</u>","text":"<u>h</u>","html":"<u>h</u>"}],"langContent":"CN"},{"id":820731581,"gmtCreate":1633429963895,"gmtModify":1633429964144,"author":{"id":"3578694659764112","authorId":"3578694659764112","name":"haiguan","avatar":"https://static.tigerbbs.com/33f51337170e6c746d423036e25009fe","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820731581","repostId":1124184351,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6099364,"gmtCreate":1633430645156,"gmtModify":1634721398331,"authorId":3562921834163798,"author":{"id":3562921834163798,"authorId":3562921834163798,"name":"ILFTS","avatar":"https://static.tigerbbs.com/4e8eb567072e2b7f82acb5ce6ecab099","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820731581,"type":1,"supId":0,"prevId":0,"content":"Liked please","text":"Liked please","html":"Liked please"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":64,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124184351"}